A bipartisan group of 10 lawmakers has filed legislation in the Maine House of Representatives to bring the state’s medical marijuana system more in line with regulations already applied to the adult-use market.
The proposal, House Bill 1847, was introduced today and referred to the Committee on Veterans and Legal Affairs.
Titled “An Act to Institute Testing and Tracking of Medical Use Cannabis and Cannabis Products Similar to Adult Use Cannabis and Cannabis Products,” the bill would require mandatory testing for medical marijuana products, including screening for THC potency, harmful microbes, pesticides, and PFAS chemicals. Dispensaries and caregivers would be prohibited from selling medical cannabis unless it has passed the required safety testing.
In addition to implementing stricter oversight, the bill would create a statewide tracking system for medical marijuana, ensuring cannabis is traceable from cultivation to retail. It also sets clear THC potency limits for edibles—10 milligrams per serving and 200 milligrams per package—and outlines rules for packaging, labeling, and sample collection.
The bill would also dedicate a portion of revenue from adult-use cannabis taxes to fund public health and safety campaigns related to the medical program. Another provision would require blister packaging for marijuana gummies sold in the adult-use market.
Finally, the bill calls for the creation of a 13-member study group to examine youth marijuana consumption in Maine. The group will investigate cannabis use among those under 21, review the effects of marijuana on youth health, and develop strategies to improve data quality and public education. A report with recommendations is due to the Legislature by December 3, 2025.
The legislation was spearheaded by Representative James Graham (D) of North Yarmouth, with bipartisan support from lawmakers in both chambers.
